Eligo Bioscience
Eligo | In vivo gene editing of the microbiome
Paris, France · Founded 2014 · $57.5M raised
- Headquarters
- Paris
- Employees
- 11–50
- Founded
- 2014
- Business Model
- B2B
- Website
- eligo-bioscience.com
- Total Funding
- $57.5M
- Last Round
- $5.0M GrantMay 2025
- Rounds
- 4
About
Eligo Bioscience is a clinical-stage biotechnology company developing in vivo gene editing medicines that precisely target the microbiome. Their proprietary GEM (Gene Editing of the Microbiome) platform uses phage-derived delivery systems to edit bacterial genes inside the body, enabling precision treatment of diseases in oncology, inflammation, and autoimmunity driven by specific microbial gene expression.
Summary
Eligo Bioscience is a Biotech company based in Paris, France, founded in 2014. It has raised $57.5M in total across 4 rounds, most recently a $5.0M Grant round in May 2025. Investors include Seventure Partners, Khosla Ventures and CARB-X.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...